美国食品和药物管理局关于埃米齐祖马布的不良事件报告系统数据库的现实药监分析
Tianyi Li1, Dongping Huang2, Yizhi Jiang3
1Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
治疗A型血友病的Emicizumab可能会引起关节疼痛和注射部位反应等不良反应. 当与aPCC或rFVIIa结合时,特别是在前90天内,观察到血栓形成的风险增加.
科学领域:
- 药物监督管理
- 血液学
- 临床治疗方法
背景情况:
- 艾米齐祖马布改变了血友病A的治疗方法,但对不良事件 (AEs) 提出了担忧.
- 了解埃米齐祖马布的安全性,特别是在组合治疗中,对于患者的护理至关重要.
研究的目的:
- 使用FAERS数据对与埃米齐祖马布相关的不良事件进行回顾性分析.
- 在单独使用或与其他止血药物一起使用时,调查副作用的发生时间和确定风险.
主要方法:
- 2017年至2023年的FDA不良事件报告系统 (FAERS) 数据库的不成比例分析.
- 应用已确定的算法 (ROR,PRR,BCPNN,MGPS) 来评估AE相关性
- 分析AE发病时间以确定时间模式.
主要成果:
- 常见的副作用包括关节疼痛和注射部位反应,符合现有的药物信息.
- 当艾米齐祖马布与激活型血栓复合物缩剂 (aPCC) 或重组激活型因子VII (rFVIIa) 联合使用时,发现血栓事件的风险增加.
- 副作用的发病时间中位数为106天,近一半发生在治疗开始后的90天内.
结论:
- 在接受艾米齐祖马布治疗的患者中,对不良事件的早期监测至关重要.
- 意识到潜在的血栓形成风险,特别是结合疗法,可以指导临床决策.
- 积极的治疗策略对于缓解AE和改善血友病A治疗患者的结果至关重要.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Analysis of Population Pharmacokinetic Data
